- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI to begin phase-III trials for FS069
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left ventricularopacification and to enhance endocardial border delineation. MBIdeveloped Albunex, which is marketed in the U.S. by MallinckrodtMedical. Mallinckrodt also has marketing rights to FS069 (SCAN9/13/95).
The Nonexistence of Perfect Balance in Radiology
September 16th 2024In the elusive pursuit of reconciling case volume and having an appropriate number of radiologists, the proverbial windsurfer may fare better than stand-up paddleboarders and daredevil surfers at navigating the waves of the profession.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
